102 related articles for article (PubMed ID: 26285774)
1. Comparative gene-expression profiling of CD133(+) and CD133(-) D10 melanoma cells.
Roudi R; Ebrahimi M; Sabet MN; Najafi A; Nourani MR; Fomeshi MR; Samadikuchaksaraei A; Shariftabrizi A; Madjd Z
Future Oncol; 2015; 11(17):2383-93. PubMed ID: 26285774
[TBL] [Abstract][Full Text] [Related]
2. Transcriptome analysis of CD133-positive stem cells and prognostic value of survivin in colorectal cancer.
Kim ST; Sohn I; DO IG; Jang J; Kim SH; Jung IH; Park JO; Park YS; Talasaz A; Lee J; Kim HC
Cancer Genomics Proteomics; 2014; 11(5):259-66. PubMed ID: 25331798
[TBL] [Abstract][Full Text] [Related]
3. Identification of Endothelin-1 and NR4A2 as CD133-regulated genes in colon cancer cells.
Puglisi MA; Barba M; Corbi M; Errico MF; Giorda E; Saulnier N; Boninsegna A; Piscaglia AC; Carsetti R; Cittadini A; Gasbarrini A; Sgambato A
J Pathol; 2011 Oct; 225(2):305-14. PubMed ID: 21826669
[TBL] [Abstract][Full Text] [Related]
4. Phenotypic subpopulations of metastatic colon cancer stem cells: genomic analysis.
Botchkina IL; Rowehl RA; Rivadeneira DE; Karpeh MS; Crawford H; Dufour A; Ju J; Wang Y; Leyfman Y; Botchkina GI
Cancer Genomics Proteomics; 2009; 6(1):19-29. PubMed ID: 19451087
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the expressions pattern of miR-10b, 21, 200c, 373 and 520c to find the correlation between epithelial-to-mesenchymal transition and melanoma stem cell potential in isolated cancer stem cells.
Fomeshi MR; Ebrahimi M; Mowla SJ; Khosravani P; Firouzi J; Khayatzadeh H
Cell Mol Biol Lett; 2015 Sep; 20(3):448-65. PubMed ID: 26208390
[TBL] [Abstract][Full Text] [Related]
6. Putative CD133+ melanoma cancer stem cells induce initial angiogenesis in vivo.
Zimmerer RM; Matthiesen P; Kreher F; Kampmann A; Spalthoff S; Jehn P; Bittermann G; Gellrich NC; Tavassol F
Microvasc Res; 2016 Mar; 104():46-54. PubMed ID: 26656667
[TBL] [Abstract][Full Text] [Related]
7. A gene signature distinguishing CD133hi from CD133- colorectal cancer cells: essential role for EGR1 and downstream factors.
Ernst A; Aigner M; Nakata S; Engel F; Schlotter M; Kloor M; Brand K; Schmitt S; Steinert G; Rahbari N; Koch M; Radlwimmer B; Weitz J; Lichter P
Pathology; 2011 Apr; 43(3):220-7. PubMed ID: 21436631
[TBL] [Abstract][Full Text] [Related]
8. CD133 as a marker for regulation and potential for targeted therapies in glioblastoma multiforme.
Choy W; Nagasawa DT; Trang A; Thill K; Spasic M; Yang I
Neurosurg Clin N Am; 2012 Jul; 23(3):391-405. PubMed ID: 22748652
[TBL] [Abstract][Full Text] [Related]
9. CD133+ melanoma subpopulations contribute to perivascular niche morphogenesis and tumorigenicity through vasculogenic mimicry.
Lai CY; Schwartz BE; Hsu MY
Cancer Res; 2012 Oct; 72(19):5111-8. PubMed ID: 22865455
[TBL] [Abstract][Full Text] [Related]
10. [Application of genome-wide genechip for screening and identifying genes related to CD133(+)CD200(+) colorectal cancer stem cells].
Zhang S; Li L; Huang Z; Xin X; Xiao B
Nan Fang Yi Ke Da Xue Xue Bao; 2013 Dec; 33(12):1787-91. PubMed ID: 24369246
[TBL] [Abstract][Full Text] [Related]
11. Expression of multidrug resistance genes in normal and cancer stem cells.
Shervington A; Lu C
Cancer Invest; 2008 Jun; 26(5):535-42. PubMed ID: 18568776
[TBL] [Abstract][Full Text] [Related]
12. Transcriptional repression of cancer stem cell marker CD133 by tumor suppressor p53.
Park EK; Lee JC; Park JW; Bang SY; Yi SA; Kim BK; Park JH; Kwon SH; You JS; Nam SW; Cho EJ; Han JW
Cell Death Dis; 2015 Nov; 6(11):e1964. PubMed ID: 26539911
[TBL] [Abstract][Full Text] [Related]
13. Hypoxia promotes stem-like properties of laryngeal cancer cell lines by increasing the CD133+ stem cell fraction.
Wu CP; Du HD; Gong HL; Li DW; Tao L; Tian J; Zhou L
Int J Oncol; 2014 May; 44(5):1652-60. PubMed ID: 24573690
[TBL] [Abstract][Full Text] [Related]
14. Description of the CD133+ subpopulation of the human ovarian cancer cell line OVCAR3.
Guo R; Wu Q; Liu F; Wang Y
Oncol Rep; 2011 Jan; 25(1):141-6. PubMed ID: 21109969
[TBL] [Abstract][Full Text] [Related]
15. Expression of CD133 and other putative stem cell markers in uveal melanoma.
Thill M; Berna MJ; Grierson R; Reinhart I; Voelkel T; Piechaczek C; Galambos P; Jager MJ; Richard G; Lange C; Gehling UM
Melanoma Res; 2011 Oct; 21(5):405-16. PubMed ID: 21900792
[TBL] [Abstract][Full Text] [Related]
16. Targeting CD133 antigen in cancer.
Ferrandina G; Petrillo M; Bonanno G; Scambia G
Expert Opin Ther Targets; 2009 Jul; 13(7):823-37. PubMed ID: 19530986
[TBL] [Abstract][Full Text] [Related]
17. Members of the low-density lipoprotein receptor-related proteins provide a differential molecular signature between parental and CD133+ DAOY medulloblastoma cells.
Annabi B; Doumit J; Plouffe K; Laflamme C; Lord-Dufour S; Béliveau R
Mol Carcinog; 2010 Jul; 49(7):710-7. PubMed ID: 20564348
[TBL] [Abstract][Full Text] [Related]
18. CD133+ liver cancer stem cells modulate radioresistance in human hepatocellular carcinoma.
Piao LS; Hur W; Kim TK; Hong SW; Kim SW; Choi JE; Sung PS; Song MJ; Lee BC; Hwang D; Yoon SK
Cancer Lett; 2012 Feb; 315(2):129-37. PubMed ID: 22079466
[TBL] [Abstract][Full Text] [Related]
19. CD133(-) cells, derived from a single human colon cancer cell line, are more resistant to 5-fluorouracil (FU) than CD133(+) cells, dependent on the β1-integrin signaling.
Hongo K; Tanaka J; Tsuno NH; Kawai K; Nishikawa T; Shuno Y; Sasaki K; Kaneko M; Hiyoshi M; Sunami E; Kitayama J; Takahashi K; Nagawa H
J Surg Res; 2012 Jun; 175(2):278-88. PubMed ID: 21601882
[TBL] [Abstract][Full Text] [Related]
20. Identification and analysis of CD133(+) melanoma stem-like cells conferring resistance to taxol: An insight into the mechanisms of their resistance and response.
El-Khattouti A; Selimovic D; Haïkel Y; Megahed M; Gomez CR; Hassan M
Cancer Lett; 2014 Feb; 343(1):123-33. PubMed ID: 24080340
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
